Total metabolic tumor volume (TMTV) for evaluating tumor response to regorafenib in patients with advanced pretreated melanoma in the prospective phase 2 RegoMel trial
 
Total metabolic tumor volume (TMTV) for evaluating tumor response to regorafenib in patients with advanced pretreated melanoma in the prospective phase 2 RegoMel trial ■
 
Iris Dirven, Ine Dirks, Laurens Raes, Cleo Bertels, Jolien I. Kessels, Manon Vounckx, Hendrik Everaert, Jef Vandemeulebroucke, Bart Neyns
 
Abstract ■

Cohort A (n = 16) of the single-center, prospective, phase 2 clinical trial RegoMel in patients (pts) with advanced refractory melanoma investigated the objective response rate (ORR) per RECIST v1.1 based on CT imaging performed every 6 weeks (Q6W) to continuous once daily dosing of regorafenib (REGO) 80 mg. TMTV was explored as a quantitative imaging biomarker for tumor response (based on [18F]FDG-PET/ CT assessments at baseline and Q12W). To calculate TMTV, a PET threshold was automatically determined by identifying a region of homogeneous intensity in the liver on PET and CT. Application of the threshold segments candidate regions with increased FDG uptake. Subsequently, a deep learning segmentation was applied considering the PET, CT and FDG uptake map to separate malignant lesions from healthy tissue (Dirks et al. 2022). Segmentations were corrected manually when necessary. The trial met its primary endpoint with an ORR of 37.5\%. At first progression, 6 BRAF-mutant pts continued REGO in association with BRAF-/ MEK-inhibitors (BRAF/MEKi) (ORR 33 \%). Nine pts had ?2 evaluable PET/CTs during REGO monotherapy. Median baseline TMTV (n = 7) was 24.2mL (range 1.7-1542.1). In 4 pts with a RECIST partial response, TMTV decreased to 0 mL (complete metabolic response) during treatment and rose again at progression-preceding RECIST-progression by 12W in one pt. In all but one pt, TMTV evolution mirrored response or progression according to RECIST. The exception showed oligoprogression (1 new lesion, i.e. RECIST-progression) with a maintained metabolic response in other lesions. In 5 evaluable BRAF-mutant pts treated with REGO+BRAF/ MEKi following progression on REGO monotherapy, TMTV-changes also corresponded with RECIST-responses. Among 3 pts with stable disease (SD) on REGO+BRAF/MEKi, the pt with a decrease in TMTV (i.e. metabolic response) experienced a longer PFS-2 (24 vs. 17W). TMTV is a sensitive and specific quantitative imaging biomarker for tumor response that closely aligned with RECIST assessments and in one case preceded RECIST-progression. By evaluating the full extent of the disease, TMTV allows for a more holistic and nuanced disease evaluation. For instance, TMTV provided added value in SD pts by distinguishing metabolic responders from non-responders. Given its automation potential and complementary clinical insights, integration of TMTV into clinical trials and practice warrants further exploration.